Predict your next investment

Government
drugabuse.gov

See what CB Insights has to offer

Investments

26

Portfolio Exits

3

Partners & Customers

10

About National Institute on Drug Abuse

The National Institute on Drug Abuse (NIDA) is a United States federal-government research institute whose mission is to "lead the Nation in bringing the power of science to bear on drug abuse and addiction".

National Institute on Drug Abuse Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

National Institute on Drug Abuse Investments

26 Investments

National Institute on Drug Abuse has made 26 investments. Their latest investment was in VeriSIM Life as part of their Grant - II on April 4, 2022.

CBI Logo

National Institute on Drug Abuse Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/19/2022

Grant - II

VeriSIM Life

$0.31M

Yes

1

6/9/2021

Grant

Prapela

$2.5M

Yes

1

6/9/2021

Grant

Tufts Medical Center

$2.5M

Yes

1

8/27/2020

Grant

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2019

Grant - V

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/19/2022

6/9/2021

6/9/2021

8/27/2020

12/19/2019

Round

Grant - II

Grant

Grant

Grant

Grant - V

Company

VeriSIM Life

Prapela

Tufts Medical Center

Subscribe to see more

Subscribe to see more

Amount

$0.31M

$2.5M

$2.5M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

National Institute on Drug Abuse Portfolio Exits

3 Portfolio Exits

National Institute on Drug Abuse has 3 portfolio exits. Their latest portfolio exit was Tridiuum on January 17, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/17/2022

Acquired

2

6/30/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

8/25/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/17/2022

6/30/2021

8/25/2020

Exit

Acquired

Reverse Merger

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

10

National Institute on Drug Abuse Partners & Customers

10 Partners and customers

National Institute on Drug Abuse has 10 strategic partners and customers. National Institute on Drug Abuse recently partnered with Delix Therapeutics on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/7/2021

Partner

United States

08:40 ET Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic ...

BOSTON , Dec. 7 , 2021 / PRNewswire / -- Delix Therapeutics , a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions , today announced a partnership with The National Institute on Drug Abuse , a federal scientific research institute under the U.S. Department of Health and Human Services ' National Institutes of Health , to test one of Delix Therapeutics 's lead clinical candidates , a non-hallucinogenic and non-toxic ibogaine analog , for use in treating a range of substance use disorders .

1

12/7/2021

Partner

United States

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders.

BOSTON , Dec. 7 , 2021 / PRNewswire / -- Delix Therapeutics , a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions , today announced a partnership with The National Institute on Drug Abuse , a federal scientific research institute under the U.S. Department of Health and Human Services ' National Institutes of Health , to test one of Delix Therapeutics 's lead clinical candidates , a non-hallucinogenic and non-toxic ibogaine analog , for use in treating a range of substance use disorders .

1

10/3/2017

Vendor

United States

NIDA Selects CALIBRE to Continue Support for Informatics Program Under New Contract

`` Hundreds of researchers and scientists at National Institute on Drug Abuse , universities , and clinical study sites rely on the National Institute on Drug Abuse to further their pursuit of knowledge and collaboration as they study the causes and treatment of substance abuse and addiction , '' said Dorisa Harris , Vice President of CALIBRE .

2

11/16/2016

Vendor

United States

Subscribe to see more

Subscribe to see more

10

1/26/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

12/7/2021

12/7/2021

10/3/2017

11/16/2016

1/26/2016

Type

Partner

Partner

Vendor

Vendor

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

08:40 ET Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic ...

BOSTON , Dec. 7 , 2021 / PRNewswire / -- Delix Therapeutics , a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions , today announced a partnership with The National Institute on Drug Abuse , a federal scientific research institute under the U.S. Department of Health and Human Services ' National Institutes of Health , to test one of Delix Therapeutics 's lead clinical candidates , a non-hallucinogenic and non-toxic ibogaine analog , for use in treating a range of substance use disorders .

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders.

BOSTON , Dec. 7 , 2021 / PRNewswire / -- Delix Therapeutics , a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions , today announced a partnership with The National Institute on Drug Abuse , a federal scientific research institute under the U.S. Department of Health and Human Services ' National Institutes of Health , to test one of Delix Therapeutics 's lead clinical candidates , a non-hallucinogenic and non-toxic ibogaine analog , for use in treating a range of substance use disorders .

NIDA Selects CALIBRE to Continue Support for Informatics Program Under New Contract

`` Hundreds of researchers and scientists at National Institute on Drug Abuse , universities , and clinical study sites rely on the National Institute on Drug Abuse to further their pursuit of knowledge and collaboration as they study the causes and treatment of substance abuse and addiction , '' said Dorisa Harris , Vice President of CALIBRE .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.